参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2019 — March 8,2019.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Howlader N,Noone A,Krapcho M,et al.SEER Cancer Statistics Review,1975-2014,based on November 2016 SEER data submission,posted to the SEER web site,April 2017.Bethesda,MD:National Cancer Institute, 2017.
4.Kristeleit R,Shapiro GI,Burris HA,et al.A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors.Clin Cancer Res 2017, 23:4095-4106.
5.Jacobs IJ,Menon U,Ryan A,et al.Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS):a randomised controlled trial.Lancet 2016, 387:945-956.
6.Movahedi-Lankarani S,Krishnamurti U,Bell DA,et al.Protocol for the examination of specimens from patients with primary tumors of the ovary,fallopian tube,or peritoneum.Based on AJCC/8th edition/2015 FIGO:Protocol web posting date:June 2017:College of American Pathologists, 2017.
7.Swisher EM,Lin KK,Oza AM,et al.Rucaparib in relapsed,platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1):an international,multicentre,openlabel,phase 2 trial.Lancet Oncol 2017, 18:75-87.
8.Timmerman D,Van Calster B,Testa A,et al.Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.Am J Obstet Gynecol 2016, 214:424-437.
9.Ferrell BR,Temel JS,Temin S,et al.Integration of palliative care into standard oncology care:American Society of Clinical Oncology Clinical Practice Guideline Update.J Clin Oncol 2017, 35:96-112.
10.Balasubramaniam S,Beaver JA,Horton S,et al.FDA Approval Summary:Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.Clin Cancer Res 2017.
11.Romagnolo C,Leon AE,Fabricio AS,et al.HE4,CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass:An Italian multicenter study.Gynecol Oncol 2016, 141:303-311.(https://www.daowen.com)
12.Rutten MJ,van Meurs HS,van de Vrie R,et al.Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer:a randomized controlled trial.J Clin Oncol 2017, 35:613-621.
13.Prendergast EN,Holzapfel M,Mueller JJ,et al.Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multiinstitutional cohort.Gynecol Oncol 2017, 144:274-278.
14.Yoshida A,Derchain SF,Pitta DR,et al.Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA):Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? Gynecol Oncol 2016, 140:481-485.
15.Gaitskell K,Green J,Pirie K,et al.Tubal ligation and ovarian cancer risk in a large cohort:Substantial variation by histological type.Int J Cancer 2016, 138:1076-1084.
16.Garcia YG,Juan AD,Mendiola C,et al.Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev)in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL)［abstract］.J Clin Oncol 2017, 35:Abstract 5508-5508.
17.Gershenson DM,Bodurka DC,Coleman RL,et al.Hormonal maintenance therapy for women with lowgrade serous cancer of the ovary or peritoneum.J Clin Oncol 2017, 35:1103-1111.
18.Hartmann LC,Lindor NM.The role of risk-reducing surgery in hereditary breast and ovarian cancer.N Engl J Med 2016, 374:454-468.
19.Sioulas VD,Schiavone MB,Kadouri D,et al.Optimal primary management of bulky stage IIIC ovarian,fallopian tube and peritoneal carcinoma:Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol 2017, 145:15-20.
20.Wentzensen N,Poole EM,Trabert B,et al.Ovarian cancer risk factors by histologic subtype:an analysis from the Ovarian Cancer Cohort Consortium.J Clin Oncol 2016, 34:2888-2898.
21.Nakonechny QB,Gilks CB.Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.Surg Pathol Clin 2016, 9:189-199.